BNGO - BioNano Genomics Inc Stock Price, Fair Value and News

0.63USD+0.03 (+5.00%)Market Closed

Market Summary

USD0.63+0.03

Market Closed

5.00%

BNGO Stock Price

View Fullscreen

BNGO RSI Chart

BNGO Valuation

Market Cap

42.1M

Price/Earnings (Trailing)

-0.19

Price/Sales (Trailing)

1.12

EV/EBITDA

-0.13

Price/Free Cashflow

-0.35

BNGO Price/Sales (Trailing)

BNGO Profitability

EBT Margin

-605.21%

Return on Equity

-274%

Return on Assets

-143.54%

Free Cashflow Yield

-287.08%

BNGO Fundamentals

BNGO Revenue

Revenue (TTM)

37.5M

Rev. Growth (Yr)

18.26%

Rev. Growth (Qtr)

-18.21%

BNGO Earnings

Earnings (TTM)

-226.8M

Earnings Growth (Yr)

15.36%

Earnings Growth (Qtr)

28.41%

Breaking Down BNGO Revenue

Last 7 days

Last 30 days

-3.1%

Last 90 days

-20.2%

Trailing 12 Months

-88.7%

How does BNGO drawdown profile look like?

BNGO Financial Health

Current Ratio

1.46

BNGO Investor Care

Shares Dilution (1Y)

117.92%

Diluted EPS (TTM)

-6.1

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	37.5M	0	0	0
2023	29.5M	31.5M	33.6M	36.1M
2022	20.5M	23.3M	25.9M	27.8M
2021	10.5M	13.2M	15.7M	18.0M
2020	9.4M	8.4M	7.3M	8.5M
2019	12.1M	10.9M	11.4M	10.1M
2018	9.6M	10.7M	10.8M	12.0M
2017	0	0	0	9.5M

Get all data in R, Python etc through our Historical Stock Data APIs

About BioNano Genomics Inc

Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.

CEO	Dr. Robert Erik Holmlin M.B.A., Ph.D.
WEBSITE	https://bionano.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	405

BioNano Genomics Inc Frequently Asked Questions

What is the ticker symbol for BioNano Genomics Inc? What does BNGO stand for in stocks?

BNGO is the stock ticker symbol of BioNano Genomics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of BioNano Genomics Inc (BNGO)?

As of Fri Jul 26 2024, market cap of BioNano Genomics Inc is 42.12 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BNGO stock?

You can check BNGO's fair value in chart for subscribers.

Is BioNano Genomics Inc a good stock to buy?

The fair value guage provides a quick view whether BNGO is over valued or under valued. Whether BioNano Genomics Inc is cheap or expensive depends on the assumptions which impact BioNano Genomics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BNGO.

What is BioNano Genomics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, BNGO's PE ratio (Price to Earnings) is -0.19 and Price to Sales (PS) ratio is 1.12. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BNGO PE ratio will change depending on the future growth rate expectations of investors.